Acute Ischemic Stroke Management

Initial Assessment and Treatment

Immediate neuroimaging evaluation should be performed to confirm diagnosis and guide treatment decisions, as recommended by the American College of Cardiology 1, 2
Time is brain - treatment delays significantly reduce chances of good functional outcomes, with every 30-minute delay in recanalization decreasing the chance of good outcome by 8-14%, according to the American College of Cardiology 2
Assess eligibility for intravenous thrombolysis (IV rtPA) if patient presents within 4.5 hours of symptom onset, as suggested by the American Heart Association 3, 4
Current anticoagulant use is a contraindication for IV rtPA, as noted by the American Heart Association 5

Endovascular Therapy

Endovascular therapy with stent retrievers is strongly indicated for patients with large vessel occlusion, as recommended by the American Heart Association 4, 6
Stent retrievers are preferred over other mechanical thrombectomy devices (Class I; Level of Evidence A), according to the American Heart Association 4
Combined approach using stent retrievers and aspiration techniques is recommended to achieve faster and more complete reperfusion, as suggested by the American College of Cardiology 2
Treatment should be initiated as soon as possible (groin puncture) and ideally within 6 hours of symptom onset, as recommended by the American Heart Association 6, 7
Technical goal should be TICI grade 2b/3 angiographic result to maximize probability of good functional outcome, according to the American Heart Association 4

Antithrombotic and Blood Pressure Management

Administration of aspirin is recommended within 24-48 hours after stroke onset, but should be delayed for 24 hours in patients who received thrombolytic therapy, as suggested by the American Heart Association 8
Maintain blood pressure ≤180/105 mm Hg during and for 24 hours after mechanical thrombectomy procedure, as recommended by the American Heart Association 8

Post-Procedure Care

Monitor for hemorrhagic transformation, which is a potential complication, especially if carotid stenting with antiplatelet therapy is performed, as noted by the American Heart Association 6
Intensive monitoring in a specialized stroke unit with capabilities for managing post-thrombectomy patients is recommended, according to the American Heart Association 3, 5
Early rehabilitation assessment to optimize functional recovery is suggested, as recommended by the American Heart Association 3

Common Pitfalls and Caveats

Delay in treatment initiation significantly worsens outcomes - establish rapid transfer protocols to endovascular-capable centers, as recommended by the American College of Cardiology and the American Heart Association 2, 4
Waiting to assess clinical response to IV rtPA before pursuing endovascular therapy is not recommended and may lead to worse outcomes (Class III; Level of Evidence B-R), according to the American Heart Association 4
Reocclusion risk is significant in patients with complete carotid occlusion, requiring careful monitoring and consideration of adjunctive therapies, as noted by the American Heart Association 3
Balancing anticoagulation for atrial fibrillation with risk of hemorrhagic transformation requires careful consideration in the acute post-stroke setting, as suggested by the American Heart Association 6

Treatment Approach for MCA vs ACA Stroke

Core Treatment Principles

The American Heart Association recommends that both MCA and ACA strokes follow the same fundamental acute treatment algorithm, with the primary difference being that MCA strokes have more robust evidence for endovascular intervention and higher risk of malignant edema requiring surgical decompression 9

Acute Reperfusion Therapy

Endovascular thrombectomy is strongly indicated for large vessel occlusion in both MCA and ACA territories, with treatment initiated within 6 hours of symptom onset, according to the American Heart Association 9
MCA occlusions have the strongest evidence base, with multiple randomized trials demonstrating 59-72% recanalization rates with stent retrievers in MCA territory, as recommended by the American College of Cardiology 9
ACA occlusions can be treated with intra-arterial therapy, though evidence is more limited, with patients with A1 or A2 segment occlusions included in the MR CLEAN trial, as noted by the American Heart Association 9

Key Clinical Differences

The American Academy of Neurology notes that median baseline NIHSS scores in major trials for MCA strokes are 16-17 9

Tirofiban Use in Large Vessel Occlusions with ICAD and NIHSS >5

Evidence-Based Treatment Algorithm

The American Heart Association recommends proceeding immediately with mechanical thrombectomy for patients presenting with NIHSS >5 and confirmed large vessel occlusion, regardless of whether ICAD is suspected initially 10, 11
Treatment should be initiated within 6 hours of symptom onset, though benefits extend to 24 hours in selected patients, as stated by the American Stroke Association 12
The administration of intravenous tirofiban as an adjunctive therapy during mechanical thrombectomy is supported by the European Stroke Organization, with 40-54% of patients receiving it in landmark trials, achieving favorable outcomes 10, 11

Critical Considerations for NIHSS >5

Patients with NIHSS >5 have sufficient neurological deficit to justify aggressive intervention, as the risk-benefit ratio strongly favors thrombectomy with adjunctive therapies, according to the American College of Cardiology 10, 11
The BAOCHE trial demonstrated 46% favorable outcomes versus 24% with medical therapy alone, with a significant reduction in risk, as reported by the trial authors 10

Safety Profile and Monitoring

Symptomatic intracranial hemorrhage rates were non-significantly higher but remained low, with a relative risk of 5.18, as reported by the Journal of Neurointerventional Surgery 10, 11
Hemorrhagic rates remained low even with combined angioplasty, stenting, and tirofiban administration, with a rate of 6% symptomatic ICH in the BAOCHE trial, as stated by the trial authors 10, 11
The 90-day mortality was non-significantly lower in thrombectomy groups, with a relative risk of 0.75, as reported by the Journal of Neurointerventional Surgery 10, 11

Acute Management of Right M1 Occlusion When Transfer Is Not Feasible

Immediate Medical Management

Intravenous alteplase (0.9 mg/kg, max 90 mg) should be administered within 4.5 hours of symptom onset, aiming for a door‑to‑needle time < 60 minutes; this standard of care yields recanalization in roughly 50 % of large‑vessel occlusions. 13

Blood‑Pressure Management

During and for 24 hours after thrombolytic therapy, systolic/diastolic pressure should be kept ≤ 180/105 mmHg to reduce the risk of hemorrhagic transformation; rapidly titratable agents such as labetalol or nicardipine are recommended for precise control. 14
In patients who are not receiving thrombolysis, aggressive lowering of blood pressure below the above threshold should be avoided because cerebral perfusion may depend on higher pressures. 14

Alternative Reperfusion Strategies

If mechanical thrombectomy is unavailable but intra‑arterial access exists, intra‑arterial fibrinolysis may be considered within 6 hours of symptom onset as a second‑line option. 15

Neurological Monitoring and Imaging

Serial neurological examinations should be performed every 15 minutes for the first 2 hours, then hourly for the subsequent 24 hours; repeat head CT is advised at 24 hours or immediately if clinical deterioration occurs. [16][13]

Hemorrhagic‑Transformation Surveillance

Any sudden neurological worsening, severe headache, acute hypertension, nausea, or vomiting warrants immediate head CT to detect symptomatic hemorrhage. 14
If symptomatic hemorrhage is identified, anticoagulation should be reversed promptly and neurosurgical consultation obtained. 14

Surgical Considerations

Patients who develop malignant cerebral edema should be prepared for decompressive hemicraniectomy within 48 hours; early surgery reduces mortality by approximately 50 % in younger patients with extensive MCA infarctions. 13
Early neurosurgical consultation is indicated for patients with complete MCA territory involvement or early radiographic signs of mass effect. 13

Intravenous Analgesic Management in Acute Ischemic Stroke with Dysphagia

Primary Analgesic Recommendation

Intravenous acetaminophen 1000 mg every 6 hours (maximum 4000 mg/24 h) is the preferred first‑line analgesic because it provides effective pain relief without antiplatelet activity, bleeding risk, or hemodynamic instability. – American Heart Association/American Stroke Association (AHA/ASA) recommendation. 17
Acetaminophen does not increase the risk of hemorrhagic transformation after acute ischemic stroke, unlike non‑steroidal anti‑inflammatory drugs (NSAIDs). – AHA/ASA recommendation. 17

Opioid Adjuncts for Breakthrough Pain

Low‑dose intravenous morphine 2–4 mg every 4 hours or hydromorphone 0.5–1 mg every 4 hours may be added for breakthrough pain, with strict blood‑pressure monitoring to keep systolic < 220 mmHg and diastolic < 120 mmHg. – AHA/ASA recommendation. 17
Opioids must be titrated cautiously in stroke patients to avoid respiratory depression, decreased level of consciousness, and hypotension that could compromise cerebral perfusion, especially when bilateral carotid stenoses reduce cerebrovascular reserve. – AHA/ASA recommendation. 17

Hemodynamic and Physiologic Monitoring

Blood pressure should be monitored every 15 minutes initially after analgesic administration and maintained below 220/120 mmHg in patients not receiving thrombolysis (target <180/105 mmHg if thrombolysis is given). – AHA/ASA recommendation. 17
Oxygen saturation should be kept >94 % with supplemental oxygen as needed, particularly when opioids are used. – AHA/ASA recommendation. 17
Core temperature should be maintained <38 °C; intravenous acetaminophen provides both analgesic and antipyretic benefits. – AHA/ASA recommendation (supported by additional International Stroke literature). [17][18]
Neurological status, including Glasgow Coma Scale, should be assessed every 15 minutes for the first 2 hours after any analgesic dose and then hourly for the next 24 hours, because opioid‑induced sedation can mask neurologic deterioration. – International Stroke guidelines. [18][19]

Vascular‑Anatomy‑Specific Considerations

In patients with combined vertebral‑artery occlusion, fusiform internal carotid artery (ICA) aneurysm, bilateral 50 % carotid stenoses, and a patent ICA stent, meticulous blood‑pressure management during analgesia is essential to preserve the limited cerebrovascular reserve. – AHA/ASA and neuro‑interventional surgery guidance. [20][21]22

Aspirin for Secondary Prevention (Separate from Analgesia)

Aspirin 150–300 mg should be administered within 48 hours of stroke onset for secondary prevention, delivered via nasogastric tube when dysphagia is present; this is independent of acute pain management. – International Stroke guidelines. [18][19]
Aspirin administration must be preceded by brain imaging to exclude intracerebral hemorrhage, and it should not be considered an analgesic in this context. – International Stroke guidelines. [18][19]

Common Pitfalls to Avoid

Do not withhold adequate analgesia out of concern that pain relief will mask neurologic signs; use intravenous acetaminophen first and reserve opioids for breakthrough pain, titrated carefully. – AHA/ASA recommendation. 17
Do not administer analgesics that may cause excessive blood‑pressure lowering (e.g., high‑dose opioids) without continuous hemodynamic monitoring, because patients with bilateral carotid stenoses rely on higher perfusion pressures to maintain cerebral blood flow. – AHA/ASA recommendation. 17